Pancreatic cancer (PC) is a leading cause of cancer related deaths in United States. The lack of early symptoms results in latestage
detection and a high mortality rate. Currently, the only potentially curative approach for PC is surgical resection, which is often unsuccessful
because the invasive and metastatic nature of the tumor masses makes their complete removal difficult. Consequently, patients
suffer relapses from remaining cancer stem cells or drug resistance that eventually lead to death. To improve the survival rate, the early
detection of PC is critical.
Current biomarker research in PC indicates that a serum carbohydrate antigen, CA 19-9, is the only available biomarker with approximately
90% specificity to PC. However, the efficacy of CA 19-9 for assessing prognosis and monitoring patients with PC remains contentious.
Thus, advances in technology and the detection of new biomarkers with high specificity to PC are needed to reduce the mortality
rate of pancreatic cancer.